Our integration with a world-renowned medical center equips us with patient experience that supports development of disease-specific, algorithmic-based testing approaches that provide faster answers for each patient. Whether screening patients or monitoring therapeutic management, our evaluations cover the full-spectrum of gastroenterology testing.
“Sometimes we can identify a different reason for patients’ symptoms that requires a different treatment course, and that can improve their outcome. When you can actually make a big difference like that, it’s always a test to be proud of.”
Ann Moyer, M.D., Ph.D., co-director of the Personalized Genomics Laboratory
Our difference
The latest
Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.
This "Specialty Testing" webinar describes a new serum test for bile acid malabsorption. Descriptions illustrate how the test can be used as a screening test and as a tool for therapeutic action.
As someone affected by chronic liver disease, Susan Parrott knows how it feels to live in uncertainty. But every few months, the anxiety and doubt that shadow her life fade when Mayo Clinic Laboratories test results confirm her condition is in check and she can continue living life on her own terms.
Mayo Clinic Laboratories is committed to innovation that provides the right test at the right time for the right patients. That effort always starts with identifying gaps in patient care. Filling those gaps sometimes involves not developing new tests but finding ways to make existing tests more efficient and easier for patients.
For Billy Dowell Jr., a competitive golfer, focus, determination, and course correction are essential to excelling at the sport. These skills, along with routine follow-up care and testing, are also important to navigating a life impacted by multiple chronic autoimmune conditions.
In this month's "Hot Topic," Melissa Snyder, Ph.D., co-director of the antibody immunology laboratory at Mayo Clinic, discusses celiac disease and the role of diagnostic testing algorithms.
Puanani Hopson, D.O., explains how Mayo Clinic Laboratories’ malabsorption panel can provide timelier diagnosis for children with chronic diarrhea or unexplained weight loss. The novel panel, which bundles four existing tests, requires just one stool sample.
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for alcohol use.
For a young child diagnosed with inflammatory bowel disease, an unexpected turn of events led by results of a Mayo Clinic Laboratories test freed him and his family from the bonds of frequent medical visits and expensive treatment, and opened the door to a life unencumbered by illness.
In this test specific episode of the "Answers From the Lab" podcast, Melissa Snyder, Ph.D., explains how IBDP2, when used after first-line testing has failed, can distinguish between ulcerative colitis and Crohn’s disease.
Ann Moyer, M.D., Ph.D., discusses TPNUQ, Mayo Clinic Laboratories' genotyping test for identifying patients at risk for thiopurine toxicity. Used prior to therapy initiation, our assay evaluates for nuances in both TPMT and NUDT15, which have associations to thiopurine metabolization.
In this month's "Hot Topic," Alicia Algeciras, Ph.D., DABCC, and Joshua Bornhorst, Ph.D., DABCC, discuss Alzheimer's disease CSF biomarkers.
Director of Mayo Clinic’s Infectious Diseases Serology Laboratory, Elitza Theel, Ph.D., joins a discussion about COVID-19 antibody testing in a recent story on NPR.